Iovance stock drops 90% despite historic approval for Amtagvi. Click here for a full investment analysis of IOVA stock.

Dr. Simone Steiner will focus on improving the manufacturing processes of individualized immunotherapies based onmyvac ® platform  Strasbourg, France, April 1, 2025, 5:45 p.m. CET — Transgene ...

Discover why John B. Sanfilippo & Son might be an undervalued gem. Learn about its strong dividend yield, growth metrics, and ...

IO Biotech, a Danish med-tech company, has obtained €57.5 million in venture debt financing from the European Investment Bank, with backing fro ...

Partex will deploy its proprietary AI-based drug discovery and development technology platform, which delivers diverse recommendations on alternative targets or indications and helps search and ...

The real (price adjusted) stock of orders in manufacturing was unchanged (0.0%) in January 2025 compared with December 2024 after seasonal and calendar adjustment, according to provisional figures of ...

23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced ...

— We have everything you need: full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; ...

纽约 - 市值约5700万美元的临床阶段生物制药公司IO Biotech (NASDAQ:IOBT)宣布，其治疗性癌症疫苗Cylembio®的生物制品许可申请(BLA)计划正按期进行，预计将于2025年底前向美国食品和药物管理局(FDA)提交。该公司的Cylembio®与pembrolizumab联合用药的关键性三期临床试验已于 ...